Figure 1



MW (kDa)
B Cells
T Cells
75
50
WB: NMT1
75
50
WB: NMT2
WB: GAPDH
L0
Ramos
BL2
Jurkat
MOLT4
CEM

Figure 2



120
100
80
60
40
20
0
Cell viability (%)
0
1
2
3
4
5
[Tris DBA] µg/ml
BL2
Ramos
Jurkat
CEM
T cells
B cells

Figure 3





120
100
80
60
40
20
0
NMT Activity (fmol/min/µg protein)
NMT1
NMT2
0
1
2
5
10
20
TrisDBA concentration (µM)

Figure 4A



Rabbit anti-NMT1



Rabbit anti-GAPDH

IM9: B lymphoblast

BL2: Burkitt's lymphoma

CEM: T cell leukemia

Karpas 299: T cell lymphoma

Sup-M2: ALCL

DAUDI: Burkitt's lymphoma


Ramos: Burkitt's lymphoma

BJAB: Burkitt's lymphoma

HD-MYZ: Hodgkin lymphoma

KM-H2: Hodgkin lymphoma

Figure 4B



IM9: B lymphoblast
BL2: Burkitt's lymphoma
CEM: T cell leukemia
Karpas 299: T cell lymphoma
Sup-M2: ALCL
DAUDI: Burkitt's lymphoma
Ramos: Burkitt's lymphoma
BJAB: Burkitt's lymphoma
HD-MYZ: Hodgkin lymphoma
KM-H2: Hodgkin lymphoma

Figure 5.





Effectiveness of NMT inhibitors on Burkitt's Lymphoma Cell Line Ramos in comparison to immotalized normal B lymphocytic cell line (IM9) after 48 Hours at different concentrations
Percentage of cells surviving
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
10nM
100nM
1μM
10μM
100μM
Concentration of Drug or Analog
Ramos Drug DD85646 (A)
Ramos Inactive Analog DD73226 (B)
IM9 Drug DD85646 (A)
IM9 Inactive Analog DD73226 (B)

Figure 6

A.


450
400
350
300
250
200
150
100
50
0
viability (% of control)
V5
NMT2
Ramos

B.


Ramos
NMT2
-
+
Anti NMT2
Anti GAPDH